Denali Therapeutics (DNLI) Treasury Shares (2017 - 2025)
Historic Treasury Shares for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $5.2 million.
- Denali Therapeutics' Treasury Shares rose 2961.74% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 2961.74%. This contributed to the annual value of $4.1 million for FY2024, which is 1357.18% up from last year.
- Per Denali Therapeutics' latest filing, its Treasury Shares stood at $5.2 million for Q3 2025, which was up 2961.74% from $5.1 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Treasury Shares high stood at $5.2 million for Q3 2025, and its period low was $2.6 million during Q3 2021.
- Its 5-year average for Treasury Shares is $3.7 million, with a median of $3.7 million in 2023.
- As far as peak fluctuations go, Denali Therapeutics' Treasury Shares surged by 6478.23% in 2021, and later skyrocketed by 742.99% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Treasury Shares stood at $2.6 million in 2021, then rose by 26.64% to $3.3 million in 2022, then grew by 9.14% to $3.6 million in 2023, then increased by 13.57% to $4.1 million in 2024, then grew by 25.4% to $5.2 million in 2025.
- Its Treasury Shares stands at $5.2 million for Q3 2025, versus $5.1 million for Q2 2025 and $4.8 million for Q1 2025.